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Abstract
Background: There are concerns that metal-on-metal hip implants may cause cancer. The objective of this study was to
evaluate patterns and timing of risk of cancer in patients with metal-on-metal total hip replacements (THR).
Methods: In a linkage study between the English National Joint Registry (NJR) and the Clinical Practice Research Datalink
(CPRD), we selected all THR surgeries (NJR) between 2003 and 2010 (n = 11,540). THR patients were stratified by type of
bearing surface. Patients were followed up for cancer and Poisson regression was used to derive adjusted relative rates (RR).
Results: The risk of cancer was similar in patients with hip resurfacing (RR 0.69; 95% Confidence Interval [CI] 0.39–1.22) or
other types of bearing surfaces (RR 0.96; 95% CI 0.64–1.43) compared to individuals with stemmed metal-on-metal THR. The
pattern of cancer risk over time did not support a detrimental effect of metal hip implants. There was substantial
confounding: patients with metal-on-metal THRs used fewer drugs and had less comorbidity.
Conclusions: Metal-on-metal THRs were not associated with an increased risk of cancer. There were substantial baseline
differences between the different hip implants, indicating possibility of confounding in the comparisons between different
types of THR implants.
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Introduction
Total hip replacement (THR) is a highly effective procedure
performed in patients with moderate to severe osteoarthritis [1]. It
is now ranked among the most common surgical operations
performed worldwide, with over one million procedures estimated
to be carried out annually [2,3]. Over the past few decades, metal-
on-metal hip devices gained popularity, and up to recently
accounted for approximately 14% of all THRs in England and
Wales [4,5]. The use of these devices, which have been associated
with the widespread dissemination of metal ions including cobalt
and chromium [6], has raised a number of health concerns,
including the potential risk of cancer [7,8]. The carcinogenic
properties of the materials used in these hip devices have been
demonstrated previously [7,9]. Cobalt and chromium at similar
concentration levels found in post mortem specimens, induce
carcinomas in animal models, and in addition may increase the
chance of malignant degeneration [10].
There is limited epidemiological evidence on cancer risk
following metal-on-metal THR compared with other bearing
surface types. Two recent studies showed no excess risk of any
cancer with metal-on-metal hip devices over other hip implants
[8,11]. The majority of the epidemiological studies could not
differentiate between bearing surface types (or could not make a
comparison with non metal-on-metal implants), and reported
somewhat conflicting findings [12–20]. A meta-analysis aggregat-
ing nine of these observational studies showed no increased risk of
any cancer with any THR prosthesis, although they were able to
detect an elevated risk of prostate and skin cancer [21].
A comparison between bearing surface types has many
limitations, as there is a high probability of confounding by
indication. Metal-on-metal hip replacements (in particular hip
resurfacing) are generally considered in younger and healthier
patients. It is important to study which patients are more likely to
get certain bearing surface types, as these patient characteristics
may also be associated with risk of cancer (and thereby introducing
bias). Previous studies have not evaluated these differences in
detail. To do so, this would require a linkage between high quality
registries providing information on implant details (such as the UK
National Joint Registry, NJR), and electronic health records with
information on clinical confounders and outcomes (such as the UK
Clinical Practice Research Datalink [CPRD]). Consequently, the
objectives of this study were to evaluate patterns and timing of risk
of cancer in patients with metal-on-metal THR and to identify
predictors for bearing surface types, cancer and mortality.
Methods
Data Sources
Data for this study were obtained from the General Practice
Research Database that is part of CPRD. CPRD collates the
computerised medical records of general practitioners (GPs). GPs
play a key role in the UK healthcare system, as they are
responsible for primary healthcare and specialist referrals. Patients
are semi-permanently affiliated with a practice that centralises the
medical information from the GPs, specialist referrals, and
hospitalizations. CPRD now contains computerised records for
650 GP practices, representing 8% of the British population. The
data recorded in the CPRD include demographic information,
prescription details, clinical events, preventive care provided,
specialist referrals, hospital admissions, and major outcomes since
1987 [www.CPRD.com].
CPRD has now been linked individually and anonymously to
other NHS datasets in England. This linkage is done by a trusted
third party using information on the NHS number, date of birth,
gender and postcode. The majority of patients were linked using
their NHS number. At the time of this study, 250 GP practices in
England participated in this linkage (about 40% of CPRD). The
NHS datasets that were linked to CPRD included the National
Joint Registry (NJR), which collects prospectively information on
replacement surgeries. Information in this data source includes
patient demographics (e.g. date of birth, sex, body mass index),
operation details (e.g. hospital, anaesthetics, patient ASA grade),
surgeon details (e.g. surgeon grade), procedure details (e.g. side of
joint, indication for surgery), surgical approach (e.g. total
replacement or resurfacing, cemented, materials used for the
implants, minimally invasive techniques, computer guided sur-
gery), intended thromboprophylaxis (both chemical and mechan-
ical), bonegraft used, and intraoperative events. Since April 2003,
the NJR has been collecting information on THRs performed in
England and Wales. By the end of July 2005, the mean weekly
submission of completed records had reached 2400 operations,
with 99% of all hospitals on the joint registry database submitting
data. The proportion of all relevant joint replacements performed
in England and Wales which was included in NJR was
approximately 60%. The NJR collects information for a large
number of patient and surgical characteristics. In addition, CPRD
was linked to the Hospital Episode Statistics (HES) that records
details on the dates of hospital admission, major procedures and
admission diagnoses and to death certificates (including primary
and secondary cause of death). In the UK, death certificates are
filled in upon death of a patient by a registered medical
practitioner who has attended the patient during their last period.
Death certificates are divided into two parts, containing the
original underlying cause of death (part I) and diseases that may
have contributed significantly to the death (part II). Diagnoses and
causes of death in the HES database and causes of death registry
are coded using the international classification of diseases, 10th
version (ICD-10). The linkage to CPRD was only available for
England. Data were available for the following time periods:
CPRD data (January 1987– December 2011), NJR data (April
2003– November 2010), HES data (April 1997– November 2010),
death certificate data (December 2000–November 2011). For the
linked datasets, the study period was defined as the latest data
entry for any of the linked datasets until the earliest end of data
collection. The study protocol was approved by the CPRD
Independent Scientific Advisory Committee and by the Research
Subcommittee of the NJR.
Study Populations
Motivation study cohorts. A retrospective cohort study was
conducted using CPRD, NJR and HES. Three study cohorts were
identified based on a record of THR in CPRD, NJR or HES. Data
on bearing surface type was only available in NJR (the coding in
HES and CPRD was non-specific with respect to surface type and
an analysis of anonymised free-text in CPRD only yielded limited
information). The main analyses (i.e. those evaluating bearing
surface type) were therefore conducted using the NJR cohort.
Analyses not concerning bearing surface type were conducted
using the CPRD cohort, as this data source had the largest sample
size. For the latter cohort, we compared THR patients (regardless
of bearing surface type) to matched referent subjects without THR
surgery (see below). As this was our largest cohort, this was the
only feasible way to evaluate cancer type specific rates among
THR surgical patients versus matched controls. Any increase in
cancer rate among this full THR cohort would be supportive that
some hip implant devices may elevate the risk for cancer. To assess
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the consistency between these three databases, the overall risk of
cancer following any THR was evaluated in all three databases.
Selection of THR patients and matched referent
subjects. For each data source (i.e. CPRD, NJR, and HES),
we selected all patients aged 18+ years who had a primary THR
record in the corresponding data source within the study period.
To each THR patient, up to six referent subjects without a history
of THR were selected and they were matched to each THR
patient by calendar time, age, sex, and practice. The index date for
THR patients and matched referent subjects was the date of the
primary THR. All patients had at least one year of valid data
collection prior to the index date. We excluded patients with a
recording of any cancer prior to the index date.
Follow-up. All patients were followed up from the index date
until the end of the study period (i.e. the earliest end of data
collection for any of the linked data sets), date of patient’s transfer
out of the practice or death, whichever came first. In addition,
THR patients in the NJR cohort with a bearing surface type other
than metal-on-metal were censored if they had undergone
conversion arthroplasty to a metal-on-metal hip device during
follow-up. Not censoring these patients would lead to misclassi-
fication of the exposure (i.e. metal or non-metal), and may
therefore dilute the association. We did not censor patients with
the converse situation (i.e. non-metal to metal-on-metal). These
patients were already exposed to metal hip implants and
mutagenic processes may irreversibly lead to carcinomas, even
after the conversion to non-metal hip implants.
Outcomes
All patients were followed up for an incident record of cancer
(excluding in situ and non-melanoma skin cancer) after the index
date. We used three sources for cancer outcomes, including
CPRD, HES and national death certificates. The analyses
requiring HES or death certificates were restricted to practices
participating in the linkage. Types of cancer were divided
according to the possibility of being related to metal ions and
included any cancer, haematological cancer (e.g. lymphoma,
leukaemia, or myeloma), malignant melanoma, prostate cancer,
renal cancer (bladder, ureter or kidney), or other types of cancer.
Cancer was analysed using the three data sources separately, as
none of these data sources were viewed to be ‘gold standard’
without any imperfections. However, findings that are consistent
across the different sources are more likely to concern validated
outcomes.
Confounders
We reviewed the literature to identify potential confounders that
were associated with cancer. These confounders were assessed at
the index date and included the following: age, sex, calendar year,
small-area socioeconomic status (for linked practices), smoking
status, use of alcohol, body mass index, a history of hypertension,
chronic obstructive pulmonary disease (COPD), coronary artery
disease (CAD), and a prescribing in the 6 months before of
NSAIDs or aspirin, oestrogen containing drugs, oral glucocorti-
coids, calcium/vitamin D supplements, glucose lowering agents,
statins, immunosuppressive agents, bisphosphonates, renin-angio-
tensin-aldosterone-system (RAAS) inhibitors, platelet inhibitors,
beta blockers, calcium channel blockers, diuretics and organic
nitrates. Small-area socioeconomic status, smoking status, use of
alcohol and body mass index were handled as categorical
variables, with a separate category for missing data.
Analyses
The following statistical analyses were conducted:
(1) Predictors of bearing surface type (NJR cohort), cancer (CPRD cohort)
and all-cause mortality (CPRD cohort): In order to assess
confounding by indication, we identified predictors of bearing
surface type (using the NJR cohort), in which we modelled all
of the potential confounders in a logistic regression model.
The outcome of interest was metal-on-metal bearing surface
type (stratified by stemmed or resurfacing), compared with hip
devices of other materials. In the second analysis, we identified
predictors of cancer and all-cause mortality within control
subjects, by modelling all potential confounders in a Poisson
regression model.
(2) Bias-analysis (NJR cohort): We evaluated risk of cancer within
six months following THR surgery versus matched referent
subjects, stratified by type of implant. Any altered cancer risk
in this period is unlikely to be causally related to THR and
most likely represents confounding by indication.
(3) Association between hip replacement (any type) and cancer risk (all three
cohorts): Poisson regression was used to estimate adjusted
relative rates (RRs) for cancer incidence in the hip
replacement cohorts to the referent cohorts. This analysis
was performed for all three study cohorts and repeated for the
three cancer data sources.
(4) Cumulative incidence of cancer (NJR cohort): A competing risk
model was used to estimate long-term risk of cancer, stratified
by type of bearing surface, gender, and age. Death was
considered the competing risk.
(5) Patterns and timing of cancer risk (CPRD cohort/NJR cohort): For the
first pattern analysis (CPRD cohort), we calculated RRs to
compare cancer incidence in the 6–24, 25–60, and 60+
months after the index date with that in the first six months.
This analysis was conducted within THR surgery patients, as
well as in referent subjects, in order to compare timing and
patterns. In the second analysis (NJR cohort), we analysed
cancer risk over time in patients with metal-on-metal THR
versus patients with other hip implant devices [22–25].
Results
Baseline Characteristics, and Predictors of Bearing
Surface Types
Demographical information of THR patients in NJR and
matched referent subjects is shown in Table 1 (11,540 THR
patients). Patients with metal-on-metal THR were considerably
younger (stemmed: 62.6 years, resurfacing: 54.5 years) compared
to those with other hip implants (69.4 years). Similarly, the
proportion of females was lower in individuals with metal-on-
metal hip implants. Multivariate logistic regression demonstrated
substantial differences in drug use and comorbidities between
metal-on-metal hip replacements and non-metal hip devices.
Predictors that were associated with both the bearing surface type
and cancer (and/or all-cause mortality) included age, gender,
smoking status, socioeconomic status, COPD, and use of oestrogen
containing drugs, platelet inhibitors, and beta blockers. The mean
age and gender distribution of THR cases were similar throughout
all databases (46,425 THR patients in CPRD and 19,034 in HES).
Bias-analysis (NJR Cohort)
Table 2 shows a healthy user effect during the first six months
after THR surgery. During the period of time immediately after
the THR, we observed a decreased risk of any cancer in patients
with THR (adjusted RR 0.74; 95% CI 0.57–0.95) compared with
matched referent subjects. There was a trend of differences in
Metal-on-Metal Hip Replacements and Risk of Cancer
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cancer risk between the different types of bearing surfaces during
the first six months after THR surgery.
Association between Hip Replacement and Cancer Risk
The risk of cancer was not increased in THR patients (any
bearing surface type) compared with matched referent subjects in
any of the three study cohorts and using any of the sources for
cancer outcomes (Table 3). In the CPRD THR cohort, the
adjusted RR was 0.76 (95% CI 0.73–0.79) using the CPRD for
cancer outcomes, 0.73 (95% CI 0.68–0.77) using HES for cancer
outcomes and 0.70 (95% CI 0.64–0.75) using national death
certificates. These results closely resembled those of the bias
analysis. This implies that patients undergoing THR surgery are
healthier at baseline, probably reflecting the selection for surgical
fitness. This emphasizes the need for careful timing analyses,
rather than overall associations. Similar trends were seen across all
databases. Compared with stemmed metal-on-metal hip replace-
ments (NJR cohort), risk of cancer was similar with hip resurfacing
(adjusted RR 0.69; 95% CI 0.39–1.22) or other types of bearing
surfaces (adjusted RR 0.96; 95% CI 0.64–1.43).
Table 4 displays the cumulative incidence rates of cancer over
time, stratified by bearing surface type, gender and age (NJR
cohort). Overall, we did not find an increased excess rate of cancer
in patients with metal-on-metal hip devices as compared to other
bearing surface types. Although there were higher excess rates in
specific patient groups (e.g. 80+ years males), the excess rates did
not increase over time, suggesting confounding rather than a true
causal relationship.
Patterns and Timing of Cancer Risk
Table 5 shows the risk of cancer over time within THR patients
and matched referent subjects, stratified by type of cancer (CPRD
cohort). The risk of cancer increased over time in both THR
patients and referent subjects. Figure 1 shows that risk of cancer in
patients with metal-on-metal hip devices remained constant over
time compared to individuals with hip implants of other bearing
surface types (NJR cohort).
Table 1. Baseline characteristics of patients with different types of hip replacements and matched controls (NJR cohort).
Any bearing surface type Stemmed metal-on-metal Hip resurfacing Other bearing surface
THR Controls THR Controls THR Controls THR Controls
Characteristic n =11,540 n =69,218 n =988 n =5,926 n =838 n =5,028 n =9,714 n =58,264
Follow-up time (mean, SD) 3.2 (2.1) 3.0 (2.1) 3.7 (1.7) 3.6 (1.7) 4.0 (2.0) 3.9 (2.0) 3.1 (2.1) 2.9 (2.1)
Females (%) 6,862 (59.5) 41,161 (59.5) 436 (44.1) 2,614 (44.1) 278 (33.2) 1,668 (33.2) 6,148 (63.3) 36,879 (63.3)
Age (mean, SD) 67.9 (11.0) 67.9 (11.0) 62.6 (10.9) 62.6 (10.9) 54.5 (8.2) 54.5 (8.2) 69.4 (10.4) 69.4 (10.4)
BMI (mean, SD) 28.3 (5.2) 27.4 (5.4) 28.5 (5.5) 27.5 (5.4) 28.5 (4.5) 27.8 (5.4) 28.3 (5.2) 27.3 (5.4)
Smoking status
Non-smoker 5,647 (48.9) 30,805 (44.5) 455 (46.1) 2,417 (40.8) 416 (49.6) 1,887 (37.5) 4,776 (49.2) 26,501 (45.5)
Ex-smoker 3,193 (27.7) 17,347 (25.1) 281 (28.4) 1,425 (24.0) 170 (20.3) 1,008 (20.0) 2,742 (28.2) 14,914 (25.6)
Current smoker 1,431 (12.4) 9,931 (14.3) 151 (15.3) 1,008 (17.0) 106 (12.6) 872 (17.3) 1,174 (12.1) 8,051 (13.8)
Unknown 1,269 (11.0) 11,135 (16.1) 101 (10.2) 1,076 (18.2) 146 (17.4) 1,261 (25.1) 1,022 (10.5) 8,798 (15.1)
Medical history (%)
Hypertension 4,963 (43.0) 26,805 (38.7) 356 (36.0) 1,860 (31.4) 172 (20.5) 949 (18.9) 4,435 (45.7) 23,996 (41.2)
COPD 462 (4.0) 3,620 (5.2) 20 (2.0) 263 (4.4) 9 (1.1) 84 (1.7) 433 (4.5) 3,273 (5.6)
Coronary artery disease 959 (8.3) 6,182 (8.9) 49 (5.0) 395 (6.7) 30 (3.6) 194 (3.9) 880 (9.1) 5,593 (9.6)
Recent prescriptions (%)
NSAIDs 4,991 (43.2) 8,006 (11.6) 428 (43.3) 614 (10.4) 339 (40.5) 469 (9.3) 4,224 (43.5) 6,923 (11.9)
Oestrogen containing drugs 380 (3.3) 1,995 (2.9) 29 (2.9) 159 (2.7) 41 (4.9) 139 (2.8) 310 (3.2) 1,697 (2.9)
Corticosteroids 550 (4.8) 2,944 (4.3) 55 (5.6) 196 (3.3) 16 (1.9) 96 (1.9) 479 (4.9) 2,652 (4.6)
Calcium/vitamin D 968 (8.4) 4,443 (6.4) 68 (6.9) 263 (4.4) 15 (1.8) 73 (1.5) 885 (9.1) 4,107 (7.0)
Antidiabetics 636 (5.5) 5,105 (7.4) 43 (4.4) 395 (6.7) 14 (1.7) 198 (3.9) 579 (6.0) 4,512 (7.7)
Statins 3,143 (27.2) 19,100 (27.6) 205 (20.7) 1,437 (24.2) 105 (12.5) 704 (14.0) 2,833 (29.2) 16,959 (29.1)
Immunosuppressants 198 (1.7) 631 (0.9) 23 (2.3) 48 (0.8) 11 (1.3) 31 (0.6) 164 (1.7) 552 (0.9)
Bisphosphonates 743 (6.4) 3,365 (4.9) 49 (5.0) 188 (3.2) 7 (0.8) 56 (1.1) 687 (7.1) 3,121 (5.4)
RAAS inhibitors 3,492 (30.3) 18,668 (27.0) 265 (26.8) 1,329 (22.4) 130 (15.5) 712 (14.2) 3,097 (31.9) 16,627 (28.5)
Platelet inhibitors 2,449 (21.2) 15,283 (22.1) 127 (12.9) 960 (16.2) 49 (5.8) 394 (7.8) 2,273 (23.4) 13,929 (23.9)
Beta blockers 2,080 (18.0) 11,790 (17.0) 125 (12.7) 747 (12.6) 77 (9.2) 433 (8.6) 1,878 (19.3) 10,610 (18.2)
Calcium channel blockers 2,356 (20.4) 12,120 (17.5) 179 (18.1) 854 (14.4) 73 (8.7) 410 (8.2) 2,104 (21.7) 10,856 (18.6)
Diuretics 3,345 (29.0) 17,240 (24.9) 212 (21.5) 1,086 (18.3) 82 (9.8) 445 (8.9) 3,051 (31.4) 15,709 (27.0)
Organic nitrates 488 (4.2) 3,388 (4.9) 20 (2.0) 183 (3.1) 7 (0.8) 82 (1.6) 461 (4.7) 3,123 (5.4)
Abbreviations: BMI = body mass index; COPD= chronic obstructive pulmonary disease; NJR =National Joint Registry; NSAID =non-steroidal anti-inflammatory drug;
RAAS = renin-angiotensin-aldosterone-system; SD= standard deviation; THR = total hip replacement.
doi:10.1371/journal.pone.0065891.t001
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Discussion
This study found that patients with metal-on-metal THR were
not at increased risk of cancer compared to individuals with hip
implants of other bearing surface types. The results of the patterns
of cancer risk over time did not find increases of cancer risk over
time. There were substantial differences in baseline characteristics
between patients who received metal-on metal hip implants and
those with other bearing surfaces. Elderly patients and patients
with chronic conditions were less likely to receive a metal-on-metal
THR and these factors were found to be associated with the risk of
cancer.
Comparison with Other Studies
Our findings are in line with two recent observational studies
investigating the risk of cancer in patients with metal on metal hip
replacement [8,11]. Similar to our study, these British and Finnish
studies could not find an increased risk of cancer and reported
incidence rates that were consistent with our study. However,
Table 2. Bias-analysis: Relative rates of types of cancer (recorded in the CPRD),six months after total hip replacement (recorded in
NJR, stratified by bearing surface type), compared with matched controls without THR surgery, and patients with stemmed metal-
on-metal total hip replacements (NJR cohort).
Compared with no THR
THR patients Control patients Adjusted relative
n cases rate n cases rate rate (95% CI) (a)
All total hip replacements
Any cancer 75 1.33 611 1.82 0.74 (0.57–0.95)
By bearing surface type
Stemmed metal-on-metal 3 0.84 29 0.94 0.80 (0.23–2.76)
Resurfacing 1 0.26 17 0.62 0.39 (0.05–3.12)
Other bearing surfaces 71 1.51 565 1.99 0.75 (0.59–0.96)
Haematological cancer 10 0.18 39 0.12 1.41 (0.67–2.98)
Malignant melanoma 1 0.02 19 0.06 0.26 (0.03–1.99)
Prostate cancer 12 0.21 62 0.18 1.14 (0.59–2.20)
Renal cancer 5 0.09 39 0.12 0.82 (0.31–2.16)
Other cancer 47 0.83 452 1.34 0.63 (0.46–0.86)
Abbreviations: CI = confidence interval; CPRD=Clinical Practice Research Datalink; n = number; NJR =National Joint Registry; THR= total hip replacement.
Rates are number of events per 100 person years. (a) Adjusted for small-area socioeconomic status, smoking status, use of alcohol, body mass index, a history of
hypertension, chronic obstructive pulmonary disease (COPD), coronary artery disease (CAD), and a prescribing in the 6 months before of NSAIDs or aspirin, oestrogen
containing drugs, oral glucocorticoids, calcium/vitamin D supplements, glucose lowering agents, statins, immunosuppressive agents, bisphosphonates, renin-
angiotensin-aldosterone-system (RAAS) inhibitors, platelet inhibitors, beta blockers, calcium channel blockers, diuretics, and organic nitrates.
doi:10.1371/journal.pone.0065891.t002
Table 3. Relative rates of cancer (any type as recorded in the CPRD, HES or ONS) during the total follow-up period in patients with
and without total hip replacements (as recorded in the CPRD, HES or NJR).
Age-, sex-, calendar Adjusted
Total hip replacement Controls year-adjusted relative relative rate
Cohort source Cancer source n cases rate n cases rate rate (95% CI) (95% CI) (a)
CPRD CPRD 3,752 1.62 25,786 2.11 0.77 (0.74–0.79) 0.76 (0.73–0.79)
HES 1,417 1.26 10,166 1.73 0.73 (0.69–0.77) 0.73 (0.68–0.77)
ONS 794 0.69 6,058 1.00 0.69 (0.64–0.74) 0.70 (0.64–0.75)
HES CPRD 1,640 1.69 10,614 1.99 0.85 (0.81–0.89) 0.84 (0.80–0.89)
HES 1,135 1.37 7,488 1.64 0.83 (0.78–0.89) 0.81 (0.76–0.87)
ONS 640 0.75 4,469 0.95 0.79 (0.72–0.86) 0.78 (0.72–0.85)
NJR CPRD 721 1.69 4,563 1.89 0.89 (0.83–0.96) 0.89 (0.82–0.97)
HES 399 1.34 2,701 1.59 0.84 (0.76–0.93) 0.83 (0.74–0.93)
ONS 190 0.63 1,395 0.80 0.76 (0.67–0.90) 0.80 (0.68–0.94)
Abbreviations: CI = confidence interval; CPRD=Clinical Practice Research Datalink; HES =Hospital Episode Statistics; n = number; NJR =National Joint Registry;
ONS=Office for National Statistics (death certificates).
Rates are number of events per 100 person years.
(a) Adjusted for confounders as shown in Table 2.
doi:10.1371/journal.pone.0065891.t003
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these previous studies did not have detailed information on risk
factors, with only a limited comparison of baseline characteristics
between the different types of THR. The present study found that
there is strong evidence for confounding between the different
types of THR. A Finnish cohort study, comprising 2,164 patients
with a mean follow-up of 17 years, showed an increased cancer-
related mortality rate in patients with metal-on-metal hip implants
(standardised mortality ratio [SMR] of 0.97) compared to
individuals with metal-on-polyethylene prostheses (SMR of 0.76)
[26]. However, as they did not look at incident cancer events, this
may well represent confounding by contraindication: individuals
with metal-on-polyethylene prostheses are in general older (and
may already have developed cancer) and cancer is a relative
contraindication for THR. Moreover, life expectancy may be
shortened in (prevalent) cancer patients and surgeons may
therefore decide not to perform a major elective surgery (such as
THR) in these patients. An alternative explanation of the
discrepant results is that the length of follow-up (up to 7 years)
was shorter in the present study than that in the Finnish study. It
has been shown in animal studies that there may be a long latency
in the development of tumours following exposure to metal
compounds, which may translate to a latency of 10 years in
humans [27]. Most other observational studies could not
differentiate between bearing surface types [7]. A meta-analysis
including nine of these studies compared risk of cancer in patients
with total joint arthroplasty with age- and gender-specific expected
cancer rates [21]. In line with our findings, the authors could not
find an overall increased risk of any cancer.
This study demonstrates the importance of linkages between
different electronic health records for health surveillance moni-
Table 4. Cumulative incidence (%) of any cancer (as recorded in CPRD) after total hip replacement by bearing surface type,
gender, and age categories gender, and age categories (NJR cohort).
Cumulative incidence of any cancer (95% confidence interval)
#1 years #2 years #3 years #4 years #5 years
Males
Age 18–59
All total hip replacements 0.6 (0.3–0.9) 1.2 (0.8–1.6) 1.7 (1.3–2.1) 2.4 (2.0–2.8) 3.0 (2.6–3.4)
Resurfacing 0.4 (0.0–1.4) 0.8 (0.0–1.9) 1.3 (0.1–2.5) 1.7 (0.4–3.0) 2.2 (0.8–3.6)
Stemmed metal-on-metal 0.8 (0.0–2.1) 1.6 (0.2–3.0) 2.4 (0.9–3.9) 3.5 (1.8–5.2) 4.2 (2.4–6.0)
Other bearing surfaces 0.6 (0.2–1.0) 1.3 (0.9–1.7) 1.9 (1.5–2.3) 2.6 (2.1–3.1) 3.3 (2.8–3.8)
Age 60–79
All total hip replacements 1.7 (1.2–2.2) 3.4 (2.9–3.9) 5.1 (4.5–5.7) 6.9 (6.3–7.5) 8.7 (8.0–9.4)
Resurfacing 1.4 (0.0–3.1) 3.0 (1.2–4.8) 4.5 (2.6–6.4) 6.3 (4.2–8.4) 8.0 (5.7–10.3)
Stemmed metal-on-metal 1.6 (0.0–3.2) 3.3 (1.5–5.1) 4.9 (3.0–6.8) 7.2 (5.1–9.3) 8.4 (6.2–10.6)
Other bearing surfaces 1.8 (1.2–2.4) 3.5 (2.9–4.1) 5.2 (4.6–5.8) 7.0 (6.3–7.7) 8.8 (8.1–9.5)
Age 80+
All total hip replacements 2.3 (1.0–3.6) 4.6 (3.3–5.9) 6.6 (5.2–8.0) 8.7 (7.2–10.2) 10.7 (9.1–12.3)
Resurfacing 2.8 (0.0–8.1) 5.9 (0.3–11.5) 8.2 (2.5–13.9) 12.1 (5.7–18.5) 15.2 (8.3–22.1)
Stemmed metal-on-metal 2.6 (0.0–7.2) 5.2 (0.3–10.1) 7.6 (2.5–12.7) 10.7 (5.1–16.3) 12.5 (6.7–18.3)
Other bearing surfaces 2.4 (1.0–3.8) 4.6 (3.1–6.1) 6.7 (5.2–8.2) 8.7 (7.1–10.3) 10.7 (8.9–12.5)
Females
Age 18–59
All total hip replacements 0.4 (0.1–0.7) 0.8 (0.5–1.1) 1.2 (0.9–1.5) 1.7 (1.4–2.0) 2.1 (1.7–2.5)
Resurfacing 0.4 (0.0–1.4) 0.8 (0.0–1.9) 1.2 (0.1–2.3) 1.7 (0.4–3.0) 2.2 (0.8–3.6)
Stemmed metal-on-metal 0.6 (0.0–1.7) 1.3 (0.1–2.5) 1.9 (0.6–3.2) 2.8 (1.3–4.3) 3.3 (1.7–4.9)
Other bearing surfaces 0.4 (0.1–0.7) 0.9 (0.6–1.2) 1.3 (1.0–1.6) 1.8 (1.4–2.2) 2.3 (1.9–2.7)
Age 60–79
All total hip replacements 1.2 (0.8–1.6) 2.4 (2.0–2.8) 3.6 (3.1–4.1) 4.9 (4.4–5.4) 6.2 (5.6–6.8)
Resurfacing 1.4 (0.0–3.1) 3.1 (1.3–4.9) 4.6 (2.6–6.6) 6.4 (4.3–8.6) 8.1 (5.8–10.4)
Stemmed metal-on-metal 1.3 (0.0–2.8) 2.6 (1.0–4.2) 4.0 (2.3–5.7) 5.8 (3.9–7.7) 6.8 (4.8–8.8)
Other bearing surfaces 1.2 (0.7–1.7) 2.4 (1.9–2.9) 3.6 (3.1–4.1) 4.8 (4.2–5.4) 6.1 (5.5–6.7)
Age 80+
All total hip replacements 1.7 (0.6–2.8) 3.3 (2.2–4.4) 4.8 (3.6–6.0) 6.4 (5.1–7.7) 7.9 (6.5–9.3)
Resurfacing – – – – –
Stemmed metal-on-metal 2.0 (0.0–6.1) 4.2 (0.0–8.6) 6.2 (1.6–10.8) 8.8 (3.7–13.9) 10.3 (4.9–15.7)
Other bearing surfaces 1.6 (0.4–2.8) 3.1 (1.9–4.3) 4.6 (3.3–5.9) 6.1 (4.7–7.5) 7.6 (6.1–9.1)
Abbreviations: CPRD=Clinical Practice Research Datalink.
doi:10.1371/journal.pone.0065891.t004
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toring. Whilst the NJR has excellent data on the type of prosthesis,
it contains limited data on clinical patient related variables and co-
morbidities. In our study, we have shown substantial differences in
these clinical variables between prosthesis types, and need to be
considered as confounding factors. CPRD does have very extensive
information on these variables, as well as comprehensive data on
drug and health service utilisation but does not contain detailed
surgical information. The linkage of NJR and CPRDdoes provide an
efficient tool for long-term safety monitoring of joint replacements.
Strengths and Limitations
The major strength of this study is the linkage between NJR and
CPRD which provided detailed information on bearing surface
type (NJR) as well as clinical risk factors for cancer (CPRD). Our
study had a reasonable sample size and cancer outcomes were
obtained through three independently collected databases. A
limitation is the lack of information on underlying disease severity
(which may have influenced cancer risk) and other potential
confounders. Referent subjects were not matched on osteoarthritis
(the main indication for THR), which is associated with a
decreased risk of cancer [28]. Although this may have underes-
timated our observed relationship, this is likely to be constant over
time and should not have had an impact on the patterns of cancer
risk over time. Moreover, this should not have influenced our
comparison between bearing surface types, as they should be more
or less homogenous with respect to osteoarthritis. We may not be
able to extrapolate our findings to long-term situations as some
cancers are known to have a prolonged latency since start of
exposure. In addition, as explained above, there may be a long
latency in the development of tumours following metal exposure,
although this has only been based on animal studies [27].
Conclusions and Study Implications
This study provides reassuring results with respect to the
possible signal of increased risks of cancer with metal-on-metal hip
replacements. We could not find an elevated risk of cancer with
metal-on-metal hip implants and the analyses of cancer risk over
time did not support a causal relationship. There were substantial
differences in baseline characteristics between the different types of
THR complicating the interpretation of a direct comparison
between bearing surfaces. The analyses in this study will need to
be repeated in the future longer follow-up data, in particular as
cancer latency may be prolonged for specific cancer types and
following metal exposure.
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Figure 1. Crude RR of cancer over time in CPRD (and 95% CI) in
patients with a metal-on-metal THR compared to patients with
another bearing surface THR (as recorded in NJR). Abbreviations:
CI = confidence interval; CPRD=Clinical Practice Research Datalink;
NJR =National Joint Registry.
doi:10.1371/journal.pone.0065891.g001
Table 5. Relative rates of types of cancer (as recorded in the
CPRD) over time (CPRD cohort).
Total hip replacement Controls
Time period
(months)
n
cases rate
Adjusted
RR (95% CI)
n
cases rate
Adjusted
RR (95% CI)
Any cancer
,6 290 1.31 reference 2,722 2.06 reference
6–24 870 1.48 1.13 (0.99–1.29) 6,903 2.04 0.97 (0.93–1.02)
25–60 1,260 1.56 1.17 (1.03–1.33) 9,191 2.13 0.96 (0.92–1.01)
.60 1,332 1.90 2.10 (1.84–2.41) 6,970 2.18 1.31 (1.25–1.38)
Haematological cancer
,6 32 0.14 reference 203 0.15 reference
6–24 82 0.14 0.95 (0.63–1.43) 496 0.15 0.93 (0.79–1.10)
25–60 77 0.10 0.63 (0.42–0.96) 638 0.15 0.88 (0.75–1.03)
.60 94 0.13 1.31 (0.85–2.04) 462 0.14 1.08 (0.91–1.29)
Malignant melanoma
,6 4 0.02 reference 91 0.07 reference
6–24 31 0.05 2.89 (1.02–8.19) 238 0.07 1.01 (0.79–1.28)
25–60 52 0.06 3.38 (1.22–9.38) 270 0.06 0.86 (0.67–1.09)
.60 46 0.07 4.02 (1.41–11.52) 236 0.07 1.06 (0.82–1.37)
Prostate cancer
,6 42 0.19 reference 294 0.22 reference
6–24 116 0.20 1.04 (0.73–1.48) 707 0.21 0.92 (0.81–1.06)
25–60 142 0.18 0.91 (0.64–1.29) 969 0.22 0.96 (0.84–1.10)
.60 163 0.23 1.93 (1.34–2.80) 777 0.24 1.64 (1.42–1.90)
Renal cancer
,6 23 0.10 reference 180 0.14 reference
6–24 61 0.10 0.99 (0.61–1.60) 538 0.16 1.15 (0.97–1.37)
25–60 93 0.11 1.06 (0.67–1.67) 712 0.16 1.15 (0.98–1.36)
.60 88 0.13 1.68 (1.03–2.76) 501 0.16 1.53 (1.28–1.84)
Other cancer
,6 189 0.86 reference 1,954 1.48 reference
6–24 580 0.99 1.16 (0.98–1.36) 4,924 1.45 0.97 (0.92–1.02)
25–60 896 1.11 1.28 (1.09–1.50) 6,602 1.54 0.96 (0.91–1.01)
.60 941 1.34 2.30 (1.94–2.72) 4,994 1.57 1.29 (1.22–1.36)
Abbreviations: CPRD=Clinical Practice Research Datalink; CI = confidence
interval; RR = relative rate.
doi:10.1371/journal.pone.0065891.t005
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